Skip to content
Screener

ANI Pharmaceuticals ANIP Contingent consideration fair value adjustment

Contingent consideration fair value adjustment at other companies

Insmed logo
InsmedINSM
-$46.96M-357%
Blackrock logo
BlackrockBLK
$180M+2,100%
Lifetime Brands logo
Lifetime BrandsLCUT
$0—
Lifetime Brands logo
Lifetime BrandsLCUT
$0—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$622K—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$0—

Segments

By segment

See full
Generics and Other$0—
Rare Disease and Brands$0—

Other financials

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.88B+25.6%
Enterprise value$1.82B+14.3%
P/E17.3×—
P/S1.9×-0.1×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%—
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×